Dapagliflozin,Placebo

3 trials

Sponsors

The Faculty of Medicine endownment Fund, Faculty of Medicine, Chiang Mai University, National Science, Research and Innovation Fund (NSRF)

Conditions

Atrial fibrillation in patients with cardiac implantable electronic device Atrial fibrillation in patients with cardiac implantable electronic deviceNon-alcoholic fatty liver disease Diabetes patient NAFLD DM type II Insulin resistance SGLT2 inhibitor Fatty liverPeriprocedural myocardial injury or infarction and acute kidney injury in patients with coronary artery disease with or without chronic kidney disease undergoing coronary angiography with possible percutaneous coronary intervention Coronary artery disease, chronic kidney disease, coronary angiography, percutaneoua coronary intervention, periprocedural myocardial injury, periprocedural myocardial infarction, acute kidney injury.

Phase 1

Effects of sodium glucose co-transporter-2 inhibitor on atrial arrhythmia burden in patient with cardiovascular implantable electronic device: a randomized controlled trial

Active, not recruitingTCTR20210315003

Faculty of Medicine, Chiang Mai UniversityAtrial fibrillation in patients with cardiac implantable electronic device Atrial fibrillation in patients with cardiac implantable electronic device

Start: 2021-03-16Target: 166Updated: 2026-03-30

Phase 3

Effect of dapagliflozin on Periprocedural Myocardial Injury and contrast-induced acute kidney injury

TCTR20230109004

National Science, Research and Innovation Fund (NSRF)Periprocedural myocardial injury or infarction and acute kidney injury in patients with coronary artery disease with or without chronic kidney disease undergoing coronary angiography with possible percutaneous coronary intervention Coronary artery disease, chronic kidney disease, coronary angiography, percutaneoua coronary intervention, periprocedural myocardial injury, periprocedural myocardial infarction, acute kidney injury.

Start: 2023-01-12Target: 292Updated: 2026-03-30

Phase 4

The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease

Active, not recruitingTCTR20170511001

The Faculty of Medicine endownment FundNon-alcoholic fatty liver disease Diabetes patient NAFLD DM type II Insulin resistance SGLT2 inhibitor Fatty liver

Start: 2016-12-28Target: 40Updated: 2026-03-30

Related Papers

Effects of sodium-glucose cotransporter-2 inhibitor on atrial high-rate episodes in patients with cardiovascular implantable electronic device: a randomized controlled trial.

2024-11-121 citations